Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 10,048,466	$ 25,652,083
Short-term investments	305,538	2,633,944
Accounts receivable	458,391	41,896
Other current assets	344,386	1,078,040
Total current assets	11,156,781	29,405,963
Equipment, net	457,912	986,553
Restricted cash	2,921,724	1,577,920
Other long-term assets	159,224	39,597
Total assets	14,695,641	32,010,033
Current liabilities:
Accounts payable	794,397	1,523,875
Accrued expenses	2,445,446	2,410,592
Deferred revenue	1,069,438	3,314,918
Accrued warrant liability	1,241,311	4,105,659
Current portion of note payable	351,527
Current portion of capital lease obligation	83,634	71,679
Total current liabilities	5,985,753	11,426,723
Noncurrent portion of capital lease obligation	7,522	97,602
Long-term debt	7,121,388
Commitments and contingencies
Total liabilities	13,114,663	11,524,325
Stockholders' equity:
Preferred stock, $.005 par value; 10,000,000 shares authorized, 0 shares issued and outstanding as of December 31, 2013 and December 31, 2012, respectively
Common stock, $.005 par value; 160,000,000 shares authorized, 45,182,114 shares issued and outstanding as of December 31, 2013; 80,000,000 shares authorized, 44,730,445 issued and outstanding as of December 31, 2012	225,911	223,653
Additional paid-in capital	125,508,471	123,864,830
Accumulated other comprehensive income	307,339	546,473
Accumulated deficit	(135,564,666)	(118,301,789)
Total Cleveland BioLabs, Inc. stockholders' (deficit) equity	(9,522,945)	6,333,167
Noncontrolling interest in stockholders' equity	11,103,923	14,152,541
Total stockholders' equity	1,580,978	20,485,708
Total liabilities and stockholders' equity	$ 14,695,641	$ 32,010,033